Literature DB >> 8107235

Multigenic evasion of inflammation by poxviruses.

G J Palumbo1, R M Buller, W C Glasgow.   

Abstract

Analyses of different cowpox virus (Brighton Red strain [CPV-BR]) mutants indicate that there is a minimum of three genes encoded by CPV-BR that are nonessential for virus replication in tissue culture but are involved in inhibiting the generation of an inflammatory response in the chicken embryo chorioallantoic membrane (CAM) model. The CPV-BR-encoded anti-inflammatory genes include the gene encoding the 38-kDa protein (also called 38K, crmA, SPI-2, or VV-WR-ORF-B13R), a tumor necrosis factor receptor homolog, and an unidentified gene that maps to the right end of the CPV genome. The kinetics of triggering of an inflammatory response at the site of virus infection as well as the magnitude of the response is dependent on the virus-encoded inhibitor that is deleted. Virus yields recovered from pocks decreased in proportion to the magnitude of the inflammatory response. The deletion of these identified inhibitors of inflammation was associated with attenuation of the mutant viruses in mice. These data confirm the existence of multiple poxvirus-encoded host defense modifiers whose function is to block the generation of an inflammatory response at the site of virus infection, which allows enhanced virus replication and potentially facilitates virus transmission.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8107235      PMCID: PMC236634     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Interaction of influenza virus with leukocytes and its effect on phagocytosis.

Authors:  W D Sawyer
Journal:  J Infect Dis       Date:  1969-06       Impact factor: 5.226

2.  Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype.

Authors:  R M Buller; G L Smith; K Cremer; A L Notkins; B Moss
Journal:  Nature       Date:  1985 Oct 31-Nov 6       Impact factor: 49.962

3.  Polymorphonuclear leukocyte dysfunction during influenza virus infection in chinchillas.

Authors:  J S Abramson; G S Giebink; E L Mills; P G Quie
Journal:  J Infect Dis       Date:  1981-06       Impact factor: 5.226

4.  Letter: Inhibition of human neutrophil chemotaxis by influenza virus.

Authors:  J J Schlesinger; C Ernst; L Weinstein
Journal:  Lancet       Date:  1976-03-20       Impact factor: 79.321

5.  Depression of rat neutrophil exudation and motility by influenza virus.

Authors:  P Ruutu
Journal:  Scand J Immunol       Date:  1977       Impact factor: 3.487

6.  Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase.

Authors:  G Karupiah; Q W Xie; R M Buller; C Nathan; C Duarte; J D MacMicking
Journal:  Science       Date:  1993-09-10       Impact factor: 47.728

7.  A novel dioxygenation product of arachidonic acid possesses potent chemotactic activity for human polymorphonuclear leukocytes.

Authors:  S Shak; H D Perez; I M Goldstein
Journal:  J Biol Chem       Date:  1983-12-25       Impact factor: 5.157

8.  Orthopoxvirus DNA: a comparison of restriction profiles and maps.

Authors:  J J Esposito; J C Knight
Journal:  Virology       Date:  1985-05       Impact factor: 3.616

9.  Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation.

Authors:  B Samuelsson
Journal:  Science       Date:  1983-05-06       Impact factor: 47.728

10.  Identification of a T3/T cell receptor complex in chickens.

Authors:  C L Chen; L L Ager; G L Gartland; M D Cooper
Journal:  J Exp Med       Date:  1986-07-01       Impact factor: 14.307

View more
  12 in total

1.  Production of prostaglandin E₂ in response to infection with modified vaccinia Ankara virus.

Authors:  Justin J Pollara; April H Spesock; David J Pickup; Scott M Laster; Ian T D Petty
Journal:  Virology       Date:  2012-04-23       Impact factor: 3.616

2.  Comparative Biochemical and Functional Analysis of Viral and Human Secreted Tumor Necrosis Factor (TNF) Decoy Receptors.

Authors:  Sergio M Pontejo; Ali Alejo; Antonio Alcami
Journal:  J Biol Chem       Date:  2015-05-04       Impact factor: 5.157

3.  Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model.

Authors:  T A Brandt; B L Jacobs
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

4.  Characterization of a myxoma virus-encoded serpin-like protein with activity against interleukin-1 beta-converting enzyme.

Authors:  F Petit; S Bertagnoli; J Gelfi; F Fassy; C Boucraut-Baralon; A Milon
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

5.  Protection against apoptosis by the vaccinia virus SPI-2 (B13R) gene product.

Authors:  M Dobbelstein; T Shenk
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

6.  A rabbitpox virus serpin gene controls host range by inhibiting apoptosis in restrictive cells.

Authors:  M A Brooks; A N Ali; P C Turner; R W Moyer
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

7.  Inflammasomes: caspase-1-activating platforms with critical roles in host defense.

Authors:  Lieselotte Vande Walle; Mohamed Lamkanfi
Journal:  Front Microbiol       Date:  2011-01-25       Impact factor: 5.640

Review 8.  Poxviruses Utilize Multiple Strategies to Inhibit Apoptosis.

Authors:  Daniel Brian Nichols; William De Martini; Jessica Cottrell
Journal:  Viruses       Date:  2017-08-08       Impact factor: 5.048

9.  The inflammation modulatory protein (IMP) of cowpox virus drastically diminishes the tissue damage by down-regulating cellular infiltration resulting from complement activation.

Authors:  G J Kotwal; C G Miller; D E Justus
Journal:  Mol Cell Biochem       Date:  1998-08       Impact factor: 3.842

10.  Phylogenetic and histological variation in avipoxviruses isolated in South Africa.

Authors:  Kristy Offerman; Olivia Carulei; Tertius A Gous; Nicola Douglass; Anna-Lise Williamson
Journal:  J Gen Virol       Date:  2013-07-16       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.